{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:29:26Z","timestamp":1791548966965,"version":"4.3.4"},"reference-count":68,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Gender-affirming therapy involves the use of hormones to develop the physical characteristics of the identified gender and suppressing endogenous sex hormone production. Venous thromboembolism (VTE) is a known risk of exogenous estrogen therapy, and while evidence of VTE risk among transgender women using modern gender-affirming hormone therapy (GAHT) is still emerging, it is thought to affect up to 5% of transgender women. Historically, GAHT was associated with a high risk of VTE; however, modern preparations are less thrombogenic mainly due to significantly lower doses used as well as different preparations. This review presents the available literature regarding the following four topics: (1) risk of VTE among transgender women receiving estradiol GAHT, (2) how the route of administration of estradiol affects the VTE risk, (3) perioperative management of GAHT, (4) VTE risk among adolescents on GAHT. There is a need for large, longitudinal studies of transgender women using GAHT to further characterize VTE risk and how this is affected by factors such as patient age, duration of GAHT use, tobacco use, body mass index, and comorbidities. Future studies in these areas could inform the development of clinical guidelines to improve the care of transgender people.<\/jats:p>","DOI":"10.1055\/a-2188-8898","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T23:08:42Z","timestamp":1696979322000},"page":"387-398","source":"Crossref","is-referenced-by-count":11,"title":["Venous Thromboembolism and Estrogen-Containing Gender-Affirming Hormone Therapy"],"prefix":"10.1055","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-128X","authenticated-orcid":false,"given":"Caroline","family":"Dix","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mollie","family":"Moloney","sequence":"additional","affiliation":[{"name":"Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen A.","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia"},{"name":"Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"McFadyen","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia"},{"name":"Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Australia"},{"name":"Atherothrombosis and Vascular Biology Program, Baker IDI Heart and Diabetes Institute, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jth.14626","article-title":"Transgender patients and the role of the coagulation clinician","volume":"17","author":"J M Connors","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ecl.2019.01.001","article-title":"Size and distribution of transgender and gender nonconforming populations: a narrative review","volume":"48","author":"M Goodman","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jsxm.2016.02.001","article-title":"Prevalence of transgender depends on the \u201ccase\u201d definition: a systematic review","volume":"13","author":"L Collin","year":"2016","journal-title":"J Sex Med"},{"issue":"S 01","key":"ref7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, Version 8","volume":"23","author":"E Coleman","year":"2022","journal-title":"Int J Transgender Health"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1210\/jc.2017-01643","article-title":"sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis","volume":"102","author":"S Maraka","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/blood.V63.3.657.657","article-title":"Estrogen stimulates von Willebrand factor production by cultured endothelial cells","volume":"63","author":"R L Harrison","year":"1984","journal-title":"Blood"},{"issue":"01","key":"ref10","first-page":"4","article-title":"Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study","volume":"84","author":"S Middeldorp","year":"2000","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2004.09.014","article-title":"Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature","volume":"116","author":"F Cosman","year":"2005","journal-title":"Thromb Res"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1538-7836.2005.01690.x","article-title":"Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response","volume":"4","author":"M van Rooijen","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2141.1997.192707.x","article-title":"Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives","volume":"97","author":"J Rosing","year":"1997","journal-title":"Br J Haematol"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1055\/s-0038-1648985","article-title":"Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives","volume":"72","author":"L A Norris","year":"1994","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/jth.15256","article-title":"Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen","volume":"19","author":"L JJ Scheres","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.thromres.2010.08.010","article-title":"Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study","volume":"126","author":"M K Barsoum","year":"2010","journal-title":"Thromb Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/JBM.S166780","article-title":"Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy","volume":"10","author":"Z Goldstein","year":"2019","journal-title":"J Blood Med"},{"issue":"03","key":"ref18","first-page":"CD010813","article-title":"Combined oral contraceptives: venous thrombosis","author":"M de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an endocrine society clinical practice guideline","volume":"102","author":"W C Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1210\/jc.2007-1809","article-title":"Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience","volume":"93","author":"L J Gooren","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1538-7836.2012.04662.x","article-title":"Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH","volume":"10","author":"T Baglin","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2015-08-665927","article-title":"Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use","volume":"127","author":"I Martinelli","year":"2016","journal-title":"Blood"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"bvab011","DOI":"10.1210\/jendso\/bvab011","article-title":"Hormone therapy, mental health, and quality of life among transgender people: a systematic review","volume":"5","author":"K E Baker","year":"2021","journal-title":"J Endocr Soc"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"M D Silverstein","year":"1998","journal-title":"Arch Intern Med"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.amjmed.2004.01.018","article-title":"Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology","volume":"117","author":"M Cushman","year":"2004","journal-title":"Am J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"f5298","DOI":"10.1136\/bmj.f5298","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis","volume":"347","author":"B H Stegeman","year":"2013","journal-title":"BMJ"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"e12763","DOI":"10.1002\/rth2.12763","article-title":"Hormonal therapies and venous thrombosis: considerations for prevention and management","volume":"6","author":"C LaVasseur","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ijgo.12455","article-title":"A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception","volume":"141","author":"M V Dragoman","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"k4810","DOI":"10.1136\/bmj.k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Y Vinogradova","year":"2019","journal-title":"BMJ"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1055\/s-0037-1613379","article-title":"Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use","volume":"89","author":"M Abdollahi","year":"2003","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref31","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.amjmed.2005.03.012","article-title":"Obesity as a risk factor in venous thromboembolism","volume":"118","author":"P D Stein","year":"2005","journal-title":"Am J Med"},{"issue":"7305","key":"ref32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.323.7305.131","article-title":"Third generation oral contraceptives and risk of venous thrombosis: meta-analysis","volume":"323","author":"J M Kemmeren","year":"2001","journal-title":"BMJ"},{"issue":"04","key":"ref33","first-page":"CD002978","article-title":"Oral oestrogen and combined oestrogen\/progestogen therapy versus placebo for hot flushes","volume":"2004","author":"A H Maclennan","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/oxfordjournals.bmb.a072592","article-title":"Combined oral contraceptives: risks and benefits","volume":"49","author":"M Thorogood","year":"1993","journal-title":"Br Med Bull"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"e2020023549","DOI":"10.1542\/peds.2020-023549","article-title":"Thrombosis risk in transgender adolescents receiving gender-affirming hormone therapy","volume":"147","author":"E S Mullins","year":"2021","journal-title":"Pediatrics"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/00016348209156956","article-title":"Estrogenic potency of oral replacement therapy estimated by the induction of pregnancy zone protein","volume":"61","author":"S Helgason","year":"1982","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"741866","DOI":"10.3389\/fendo.2021.741866","article-title":"Risk of venous thromboembolism in transgender people undergoing hormone feminizing therapy: a prevalence meta-analysis and meta-regression study","volume":"12","author":"M Totaro","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1373\/clinchem.2018.288316","article-title":"Venous thrombotic risk in transgender women undergoing estrogen therapy: a systematic review and metaanalysis","volume":"65","author":"J Khan","year":"2019","journal-title":"Clin Chem"},{"issue":"11","key":"ref39","first-page":"CD013138","article-title":"Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women","volume":"11","author":"C Haupt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"07","key":"ref40","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jsxm.2021.04.006","article-title":"Risk for venous thromboembolism in transgender patients undergoing cross-sex hormone treatment: a systematic review","volume":"18","author":"V S Kotamarti","year":"2021","journal-title":"J Sex Med"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2265.1997.2601068.x","article-title":"Mortality and morbidity in transsexual subjects treated with cross-sex hormones","volume":"47","author":"P J van Kesteren","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"09","key":"ref42","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0026-0495(89)90233-3","article-title":"Mortality and morbidity in transsexual patients with cross-gender hormone treatment","volume":"38","author":"H Asscheman","year":"1989","journal-title":"Metabolism"},{"issue":"10","key":"ref43","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-2005-865900","article-title":"Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist","volume":"113","author":"R Dittrich","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jsxm.2016.09.001","article-title":"Incidence of venous thromboembolism in transgender women receiving oral estradiol","volume":"13","author":"J D Arnold","year":"2016","journal-title":"J Sex Med"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF01579291","article-title":"Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism","volume":"18","author":"J C Prior","year":"1989","journal-title":"Arch Sex Behav"},{"issue":"04","key":"ref46","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.fertnstert.2008.12.017","article-title":"Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy","volume":"93","author":"J Ott","year":"2010","journal-title":"Fertil Steril"},{"issue":"08","key":"ref47","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/jsm.12571","article-title":"Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence","volume":"11","author":"K Wierckx","year":"2014","journal-title":"J Sex Med"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1530\/EJE-13-0493","article-title":"Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study","volume":"169","author":"K Wierckx","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"02","key":"ref49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1530\/EJE-19-0463","article-title":"Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria","volume":"182","author":"G Meyer","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"07","key":"ref50","first-page":"dgaa262","article-title":"Global coagulation assays in transgender women on oral and transdermal estradiol therapy","volume":"105","author":"H Y Lim","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"04","key":"ref51","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/GME.0000000000001938","article-title":"Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events: a scoping review","volume":"29","author":"T H Sobel","year":"2022","journal-title":"Menopause"},{"issue":"12","key":"ref52","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1701-2163(16)30342-5","article-title":"Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation","volume":"25","author":"W O Spitzer","year":"2003","journal-title":"J Obstet Gynaecol Can"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/13625180008500402","article-title":"The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives","volume":"5","author":"A L Nightingale","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"10","key":"ref54","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1111\/j.1743-6109.2012.02876.x","article-title":"Long-term evaluation of cross-sex hormone treatment in transsexual persons","volume":"9","author":"K Wierckx","year":"2012","journal-title":"J Sex Med"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/26895269.2022.2025551","article-title":"Thrombophilia and hormonal therapy in transgender persons: a literature review and case series","volume":"23","author":"M Kerrebrouck","year":"2022","journal-title":"Int J Transgender Health"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1160\/TH04-11-0759","article-title":"Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study","volume":"94","author":"O Wu","year":"2005","journal-title":"Thromb Haemost"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejim.2020.10.014","article-title":"Long-term recurrence risk after a first venous thromboembolism in men and women under 50 years old: a French prospective cohort","volume":"84","author":"C de Moreuil","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"04","key":"ref58","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M17-2785","article-title":"Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study","volume":"169","author":"D Getahun","year":"2018","journal-title":"Ann Intern Med"},{"issue":"7655","key":"ref59","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.39555.441944.BE","article-title":"Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis","volume":"336","author":"M Canonico","year":"2008","journal-title":"BMJ"},{"issue":"04","key":"ref60","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/PRS.0000000000007786","article-title":"Perioperative transgender hormone management: avoiding venous thromboembolism and other complications","volume":"147","author":"R Hontscharuk","year":"2021","journal-title":"Plast Reconstr Surg"},{"issue":"06","key":"ref61","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10508-006-9104-9","article-title":"Patient-reported complications and functional outcomes of male-to-female sex reassignment surgery","volume":"35","author":"A A Lawrence","year":"2006","journal-title":"Arch Sex Behav"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"168e","DOI":"10.1097\/PRS.0b013e318254b4ee","article-title":"Evidence-based practices for thromboembolism prevention: summary of the ASPS Venous Thromboembolism Task Force Report","volume":"130","author":"R X Murphy Jr","year":"2012","journal-title":"Plast Reconstr Surg"},{"issue":"02","key":"ref63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamasurg.2018.4598","article-title":"Association of surgical risk with exogenous hormone use in transgender patients: a systematic review","volume":"154","author":"E R Boskey","year":"2019","journal-title":"JAMA Surg"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1076029619838052","DOI":"10.1177\/1076029619838052","article-title":"Completion of the updated caprini risk assessment model (2013 Version)","volume":"25","author":"M Cronin","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"02","key":"ref65","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/01.prs.0000475790.54231.28","article-title":"Benefits and risks of prophylaxis for deep venous thrombosis and pulmonary embolus in plastic surgery: a systematic review and meta-analysis of controlled trials and consensus conference","volume":"137","author":"C J Pannucci","year":"2016","journal-title":"Plast Reconstr Surg"},{"issue":"07","key":"ref66","first-page":"2511","article-title":"Continuing perioperative estrogen therapy does not increase venous thromboembolic events in transgender patients: a systematic review and meta-analysis","volume":"26","author":"J Badreddine","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jsxm.2020.10.018","article-title":"Estrogen continuation and venous thromboembolism in penile inversion vaginoplasty","volume":"18","author":"I T Nolan","year":"2021","journal-title":"J Sex Med"},{"issue":"04","key":"ref68","doi-asserted-by":"crossref","first-page":"e1586","DOI":"10.1210\/clinem\/dgaa966","article-title":"No venous thromboembolism increase among transgender female patients remaining on estrogen for gender-affirming surgery","volume":"106","author":"A Kozato","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"02","key":"ref69","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/26895269.2020.1753136","article-title":"Epidemiological considerations in transgender health: a systematic review with focus on higher quality data","volume":"21","author":"Q Zhang","year":"2020","journal-title":"Int J Transgender Health"},{"issue":"05","key":"ref70","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1023\/A:1018704630036","article-title":"A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients","volume":"27","author":"K Schlatterer","year":"1998","journal-title":"Arch Sex Behav"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2020.05.008","article-title":"Estrogen and thrombosis: a bench to bedside review","volume":"192","author":"M Y Abou-Ismail","year":"2020","journal-title":"Thromb Res"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2188-8898.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:42:38Z","timestamp":1730810558000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2188-8898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":68,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2024,4,23]]},"published-print":{"date-parts":[[2024,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2188-8898","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,10]]},"published":{"date-parts":[[2023,10,10]]}}}